Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of Tozorakimab Dosage Forms
NCT06304961Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2024
- Primary completion
- Sep 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tozorakimab in chronic obstructive pulmonary disease (COPD) and asthma (2 arms), sponsored by AstraZeneca. Primary endpoints: Area under the concentration-time curve from time 0 to infinity at Day 113, Area under the concentration-curve from time 0 to the last quantifiable concentration at Day 113 and 1 more. Started Apr 2024; status: completed.
02
Drugs
tozorakimab
03
Conditions
chronic obstructive pulmonary disease (COPD)asthma
Beyond the preview
Go deeper on NCT06304961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06304961.